Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
213Bi-DTPA-PAN-622
- Development stage
- Preclinical
- Lead developer
- Panacea Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
213Bi-DTPA-PAN-622 is a radioimmunotherapy (RIT) candidate developed by Panacea Pharmaceuticals for the treatment of acute myeloid leukemia (AML). It comprises a fully human monoclonal antibody, PAN-622, which specifically targets human aspartyl (asparaginyl) β-hydroxylase (HAAH), an embryonic protein that is overexpressed on the surface of various malignant cells, including AML cells, but is absent on normal leukocytes. The antibody is conjugated via a DTPA-maleimide chelator to Bismuth-213 (213Bi), a short-lived alpha-emitting radionuclide. Upon binding to HAAH-expressing leukemia cells, the alpha particles deliver high-energy radiation that induces lethal DNA damage, providing a targeted therapeutic approach with a potentially favorable therapeutic index.
- Other names
- Bismuth-213-DTPA-PAN-622Bismuth213-DTPA-PAN-622Bismuth 213-DTPA-PAN-622213Bi-PAN-622
02
Targets
ASPH (Aspartyl/asparaginyl beta-hydroxylase)
Beyond the preview
Go deeper on 213Bi-DTPA-PAN-622.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 213Bi-DTPA-PAN-622.